Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04486482 · ClinicalTrials.gov registry record · NA
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
A NA study, sponsored by Kaleido Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT04486482 is a NA study that has completed, run by Kaleido Biosciences. The registered enrollment target is 49 participants.
The verdict
NCT04486482, a NA study, has completed, sponsored by Kaleido Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
Interventions
- OTHER KB109 + Self Supportive Care (SSC)
- OTHER Self Supportive Care (SSC) Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2021-01-12 |
| Est. Completion | 2021-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04486482
The ClinicalTrials.gov registry entry for NCT04486482 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaleido Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KB109 + Self Supportive Care (SSC) is the first listed.
NCT04486482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04486482 about?
NCT04486482 is a clinical study titled "A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function". This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
What is the current status of trial NCT04486482?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2021-01-12. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT04486482?
The interventions under investigation include: KB109 + Self Supportive Care (SSC) (OTHER), Self Supportive Care (SSC) Alone (OTHER).
Who is sponsoring clinical trial NCT04486482?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.